Ofatumumab

Overview

Journal MAbs

Specialty Allergy & Immunology

Date 2010 Jan 14

PMID 20068404

Citations 25

Authors

Bodi Zhang

Affiliations

Soon will be listed here.

Abstract

Ofatumumab is an anti-CD20 IgG1kappa human monoclonal antibody that is being considered by the US Food and Drug Administration and the European Medicines Agency for marketing approval as a treatment for chronic lymphocytic leukemia. The mAb is also being studied as a treatment for lymphoma, rheumatoid arthritis and multiple sclerosis. The candidate targets the same antigen as rituximab, but ofatumumab binds a novel, membrane-proximal epitope, and dissociates from its target at a slower rate compared to rituximab. Ofatumumab might be approved in the US by August 2009.

Citing Articles

CAR T-cell therapy for systemic lupus erythematosus: current status and future perspectives.

Zhou J, Lei B, Shi F, Luo X, Wu K, Xu Y Front Immunol. 2025; 15:1476859.

PMID: 39749335 PMC: 11694027. DOI: 10.3389/fimmu.2024.1476859.

Case report: The case report of ofatumumab, a fully human anti-CD20 monoclonal antibody, in the treatment of KLHL11 encephalitis.

Deng M, Zeng F, Kong Z, Li T Front Immunol. 2024; 15:1456840.

PMID: 39575244 PMC: 11578727. DOI: 10.3389/fimmu.2024.1456840.

Cancer immunotherapies: A hope for the uncurable?.

Hamdan F, Cerullo V Front Mol Med. 2024; 3:1140977.

PMID: 39086690 PMC: 11285639. DOI: 10.3389/fmmed.2023.1140977.

A Comprehensive Review on the Efficacy of Anti-CD20 Therapies in Pemphigus Treatment.

Khan A, Singh A, Madke B, Bhatt D, Jangid S Cureus. 2024; 16(4):e58834.

PMID: 38784354 PMC: 11114485. DOI: 10.7759/cureus.58834.

Myasthenia gravis: the changing treatment landscape in the era of molecular therapies.

Iorio R Nat Rev Neurol. 2024; 20(2):84-98.

PMID: 38191918 DOI: 10.1038/s41582-023-00916-w.

References

Kohler G, Milstein C . Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975; 256(5517):495-7. DOI: 10.1038/256495a0. View

Teeling J, Mackus W, Wiegman L, van den Brakel J, Beers S, French R . The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol. 2006; 177(1):362-71. DOI: 10.4049/jimmunol.177.1.362. View

Waaler E . On the occurrence of a factor in human serum activating the specific agglutintion of sheep blood corpuscles. 1939. APMIS. 2007; 115(5):422-38. DOI: 10.1111/j.1600-0463.2007.apm_682a.x. View

Nikbin B, Mohyeddin Bonab M, Khosravi F, Talebian F . Role of B cells in pathogenesis of multiple sclerosis. Int Rev Neurobiol. 2007; 79:13-42. DOI: 10.1016/S0074-7742(07)79002-5. View

Bleeker W, Munk M, Mackus W, van den Brakel J, Pluyter M, Glennie M . Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. Br J Haematol. 2007; 140(3):303-12. DOI: 10.1111/j.1365-2141.2007.06916.x. View

Beum P, Lindorfer M, Beurskens F, Stukenberg P, Lokhorst H, Pawluczkowycz A . Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J Immunol. 2008; 181(1):822-32. DOI: 10.4049/jimmunol.181.1.822. View

Kosmas C, Stamatopoulos K, Stavroyianni N, Tsavaris N, Papadaki T . Anti-CD20-based therapy of B cell lymphoma: state of the art. Leukemia. 2002; 16(10):2004-15. DOI: 10.1038/sj.leu.2402639. View

Reff M, Carner K, Chambers K, Chinn P, Leonard J, Raab R . Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994; 83(2):435-45. View

Gopal A, Press O . Clinical applications of anti-CD20 antibodies. J Lab Clin Med. 1999; 134(5):445-50. DOI: 10.1016/s0022-2143(99)90164-6. View

10.

Alexander D, Mink P, Adami H, Chang E, Cole P, Mandel J . The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer. 2007; 120 Suppl 12:1-39. DOI: 10.1002/ijc.22719. View

11.

Teeling J, French R, Cragg M, van den Brakel J, Pluyter M, Huang H . Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood. 2004; 104(6):1793-800. DOI: 10.1182/blood-2004-01-0039. View

12.

Leandro M, Edwards J, Cambridge G . Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis. 2002; 61(10):883-8. PMC: 1753912. DOI: 10.1136/ard.61.10.883. View

13.

Bubien J, Zhou L, Bell P, Frizzell R, Tedder T . Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J Cell Biol. 1993; 121(5):1121-32. PMC: 2119683. DOI: 10.1083/jcb.121.5.1121. View

14.

Edwards J, Cambridge G . Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford). 2001; 40(2):205-11. DOI: 10.1093/rheumatology/40.2.205. View

15.

Press O, Appelbaum F, Ledbetter J, Martin P, Zarling J, Kidd P . Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood. 1987; 69(2):584-91. View

16.

Coiffier B, Lepretre S, Moller Pedersen L, Gadeberg O, Fredriksen H, van Oers M . Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood. 2007; 111(3):1094-100. DOI: 10.1182/blood-2007-09-111781. View

17.

Hagenbeek A, Gadeberg O, Johnson P, Moller Pedersen L, Walewski J, Hellmann A . First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood. 2008; 111(12):5486-95. DOI: 10.1182/blood-2007-10-117671. View